Point Therapeutics to Host Fourth Quarter and Fiscal Year 2005 Results Conference Call/Audio Webcast

Point Therapeutics, Inc. (NASDAQ: POTP), announced today
that it will release fourth quarter and fiscal year 2005 results on
Tuesday, March 14, 2006, after the close of the U.S. financial
markets. A conference call will follow at 4:30 PM Eastern Time, to
review the results and provide an update on the Company's progress.
Additionally, Point will discuss the recent Keystone Symposium
presentation on the Company's type 2 diabetes program (PT-630). The
Keystone presentation is available for review by visiting the investor
relations page at www.pther.com.
   Participants are invited to attend the call by visiting
www.pther.com or by dialing:
-0-
*T
            1-866-510-0710 (International: 617-597-5378)
            Passcode: 25591960
*T
   A re-broadcast of the conference call will be available until
March 28, 2006 and accessible by dialing:
-0-
*T
            1-888-286-8010 (International: 617-801-6888)
            Passcode: 89953608
*T
   About Point Therapeutics, Inc.:

   Point is a Boston-based biopharmaceutical company developing a
portfolio of dipeptidyl peptidase (DPP) inhibitors for use in cancer,
type 2 diabetes and as vaccine adjuvants. Point is currently studying
its lead product candidate, talabostat, in two Phase 3 trials in
non-small cell lung cancer. Point is also studying talabostat in
several Phase 2 trials, including as a single-agent in metastatic
melanoma, in combination with cisplatin in metastatic melanoma, in
combination with rituximab in advanced chronic lymphocytic leukemia,
and in combination with gemcitabine in metastatic pancreatic cancer.
In addition, Point's portfolio includes two other DPP inhibitors in
preclinical development--PT-630 for type 2 diabetes, and PT-510 as a
vaccine adjuvant.

   Certain statements contained herein are not strictly historical
and are "forward looking" statements as defined in the Private
Securities Litigation Reform Act of 1995. This information includes
statements with respect to the company's clinical development programs
and the timing of initiation and completion of its clinical trials.
Forward-looking statements are statements that are not historical
facts, and can be identified by, among other things, the use of
forward-looking language, such as "believes," "feels," "expects,"
"may," "will," "should," "seeks," "plans," "schedule to,"
"anticipates" or "intends" or the negative of those terms, or other
variations of those terms of comparable language, or by discussions of
strategy or intentions. A number of important factors could cause
actual results to differ materially from those projected or suggested
in the forward looking statement, including the risk factors described
in Point's quarterly report on Form 10-Q for the quarter ended
September 30, 2005 and from time to time in Point's periodic and other
reports filed with the Securities and Exchange Commission.